Viking Therapeutics
VKTX
387 hedge funds and large institutions have $4.26B invested in Viking Therapeutics in 2024 Q2 according to their latest regulatory filings, with 91 funds opening new positions, 165 increasing their positions, 102 reducing their positions, and 72 closing their positions.
128% more call options, than puts
Call options by funds: $421M | Put options by funds: $185M
62% more repeat investments, than reductions
Existing positions increased: 165 | Existing positions reduced: 102
26% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 72
3% more funds holding
Funds holding: 375 → 387 (+12)
0.31% less ownership
Funds ownership: 73.25% → 72.94% (-0.31%)
35% less capital invested
Capital invested by funds: $6.57B → $4.26B (-$2.3B)
54% less funds holding in top 10
Funds holding in top 10: 13 → 6 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$152M |
| 2 |
State Street
Boston,
Massachusetts
|
+$118M |
| 3 |
JP Morgan Chase
New York
|
+$79.4M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$73.3M |
| 5 |
D.E. Shaw & Co
New York
|
+$29.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$294M |
| 2 |
BlackRock
New York
|
-$147M |
| 3 |
DM
Deerfield Management
New York
|
-$38M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$36.6M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$30.7M |
VKTX Hedge Fund Activity: Q2 2024 in Review
387 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q2 2024, worth a combined $4.26B — down 35% from $6.57B a quarter earlier.
Buyers outnumbered sellers: 91 funds opened new VKTX positions and 72 closed out — a net gain of 19 holders — while 165 added to existing stakes and 102 trimmed.
The largest buyer was Vanguard Group, adding an estimated $152M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $294M sold.
- 387 institutional investors held Viking Therapeutics (VKTX) as of Q2 2024, up from 375 in Q1 2024.
- Funds reported $4.26B of Viking Therapeutics stock for Q2 2024, down 35% quarter-over-quarter.
- 91 funds opened new Viking Therapeutics positions in Q2 2024 and 72 closed out, a net change of +19 holders.
- The largest Viking Therapeutics buyer in Q2 2024 was Vanguard Group, an estimated $152M added.
- The largest Viking Therapeutics seller in Q2 2024 was Avoro Capital Advisors, an estimated $294M sold.
Based on aggregated 13F filings for Q2 2024.